One Coordinated Team for Platforms That Keep Expanding
Implantable neurostimulator devices combine active-implant complexity with a platform that often expands into new indications over time. Each new indication brings another submission, new trial questions, and a separate coverage pathway.
This sheet outlines how RQM+ supports manufacturers of spinal cord, deep brain, sacral, and vagus nerve stimulators across regulatory, clinical, laboratory, and reimbursement work, with every function coordinated on the same program from the start.
What’s Inside
- How RQM+ plans serial label-expansion programs so each new indication for a neurostimulation platform has its regulatory path mapped in sequence
- How neuromodulation trials are built around sham-control architecture and patient-reported outcome (PRO) validation, led by teams experienced in pain management and movement disorder programs
- How Jordi Labs, our in-house, FDA-recognized laboratory, runs extractables and leachables (E&L) testing on polyurethane and silicone leads and implantable pulse generator (IPG) housing materials with validated methods already in inventory
- How Lumo™, our AI materials science platform, flags biocompatibility and E&L risks early
- Why reimbursement strategy starts on day one of program planning for platforms that will pursue several indications, each with its own coverage pathway
Who This Is For
Regulatory, clinical, quality, and market access leaders at companies developing spinal cord, deep brain, sacral, or vagus nerve stimulators, especially teams planning a platform that will reach new indications over time.
Plan the next indication while the first one is still in review. This sheet shows how RQM+ coordinates that sequence from early planning through submission.
